98%
921
2 minutes
20
Congenital hyperinsulinism (CHI) is a rare but significant cause of persistent neonatal hypoglycemia (NH), associated with a high risk of neurological complications if not promptly treated. This condition is characterized by inappropriate insulin secretion, often of genetic origin, independent of blood glucose levels. We report the case of a male macrosomic newborn admitted on the second day of life for respiratory distress, generalized seizures, and severe hypoglycemia (1.4 mmol/L) unresponsive to intravenous glucose therapy. Laboratory investigations revealed elevated insulin and C-peptide levels, absence of ketone bodies, and a positive response to the glucagon stimulation test. Echocardiography showed hypertrophic cardiomyopathy without functional impairment. Due to limited resources, neither [18F]-fluoro-L-DOPA PET imaging nor genetic testing could be performed. Treatment with a combination of diazoxide and octreotide led to partial improvement, but the clinical course was unfavorable, with the infant dying at four months of age due to sepsis. This case highlights the diagnostic and therapeutic challenges of CHI in resource-limited settings. Through this clinical observation and a review of the literature, we emphasize the importance of a rigorous diagnostic approach and early, multidisciplinary, and tailored management to reduce the morbidity and mortality associated with this rare condition.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12403187 | PMC |
http://dx.doi.org/10.7759/cureus.89272 | DOI Listing |
Front Endocrinol (Lausanne)
September 2025
Congenital Hyperinsulinism International, Glen Ridge, NJ, United States.
Introduction: Congenital hyperinsulinism (HI) is a rare disease that causes severe hypoglycemia. Diazoxide is the first-line treatment; however, many individuals using diazoxide continue to experience hypoglycemia. Diazoxide is associated with side effects that impact life and well-being.
View Article and Find Full Text PDFCureus
August 2025
Mother and Child Health Laboratory, Faculty of Medicine and Pharmacy, Mohammed First University, Oujda, MAR.
Congenital hyperinsulinism (CHI) is a rare but significant cause of persistent neonatal hypoglycemia (NH), associated with a high risk of neurological complications if not promptly treated. This condition is characterized by inappropriate insulin secretion, often of genetic origin, independent of blood glucose levels. We report the case of a male macrosomic newborn admitted on the second day of life for respiratory distress, generalized seizures, and severe hypoglycemia (1.
View Article and Find Full Text PDFbioRxiv
August 2025
Department of Biochemistry, Spencer Fox Eccles School of Medicine, University of Utah, Salt Lake City, UT, USA.
Congenital hyperinsulinism (HI) is a rare genetic disease characterized by overproduction of insulin. One class of potential HI treatments is insulin receptor (IR) antagonists like S961 and Ins-AC-S2, peptides composed of binding segments for each of the IR sites capable of binding insulin: site 1 and site 2. Notably, S597 - containing the same IR binding segments as S961 but in the opposite order (site 2-site 1) - is an IR agonist rather than an antagonist.
View Article and Find Full Text PDFInt J Mol Sci
August 2025
Laboratorio de Errores Innatos del Metabolismo y Tamiz, Instituto Nacional de Pediatría, Secretaría de Salud, Mexico City 04530, Mexico.
Genome-wide paternal uniparental isodisomy mosaicism (GWpUPIDM) is an extremely rare condition characterized by varying proportions of an androgenetic cell line across different tissues. It is primarily associated with severe congenital hyperinsulinism (CHI), Beckwith-Wiedemann syndrome (BWS) stigmata, a high risk (69-79%) of developing neoplasia and, in some cases, additional manifestations of multilocus paternal imprinting disorders (MPIDs). We herein report the first Mexican/Latin American female patient GWpUPIDM presenting with non-syndromic CHI requiring subtotal pancreatectomy and persistent but unexplained asymptomatic diffuse hepatopathy.
View Article and Find Full Text PDFBol Med Hosp Infant Mex
August 2025
Departamento de Pediatría.
Background: Persistent hyperinsulinemic hypoglycemia of infancy (PHHI) affects between 0.5% and 5% of pediatric patients. This condition is caused by a dysfunction of pancreatic β-cells, leading to tumors and hyperinsulinism, which result in persistent hypoglycemia.
View Article and Find Full Text PDF